DEA issues notice of intent to temporarily place

Cresthaven Analytics Intelligence Brief

Headline

DEA issues notice of intent to temporarily place O-desmethyltramadol in Schedule I of the Controlled Substances Act

Executive Summary

The DEA published a notice of intent on June 24, 2026 to place O-desmethyltramadol (O-DSMT) in Schedule I on a temporary basis. The forthcoming order imposes full Schedule I controls and criminal, civil, and administrative sanctions on all persons who handle the substance.

Bottom Line

The notice of intent initiates the formal process under which O-DSMT becomes a Schedule I controlled substance. Upon issuance of the temporary order, all manufacture, distribution, import, export, research, and possession of O-DSMT without DEA Schedule I authorization becomes subject to criminal, civil, and administrative sanctions. Firms and institutions currently handling O-DSMT in any form, including its salts and isomers, carry an immediate obligation to assess their registration status and supply-chain exposure before the order issues.

Key Regulatory Signals

Full Schedule I Control Regime Incoming: Once the temporary order issues, every handler of O-DSMT, including manufacturers, distributors, importers, exporters, researchers, and possessors, becomes subject to the complete Schedule I regulatory framework. No grandfather period is indicated in the notice of intent.
Broad Substance Definition Captures Derivatives: The scheduling action covers O-DSMT's isomers, esters, ethers, salts, and salts of isomers, esters, and ethers. Firms handling any chemically related form of the substance must assess whether their inventory falls within the defined scope before the order issues.
Research and Analytical Use Requires DEA Authorization: Instructional activities and chemical analysis with O-DSMT are explicitly listed as regulated conduct. Academic institutions, contract research organizations, and analytical laboratories currently working with the substance must obtain Schedule I researcher registration before the order takes effect.
Criminal Sanctions Attach Upon Order Issuance: The notice confirms that criminal sanctions applicable to Schedule I substances will apply to handlers upon issuance of the temporary order. Distributors and suppliers in the gray-market novel psychoactive substance space face immediate exposure at that point.

Regulatory Delta

- Since 2018, the DEA has applied temporary Schedule I placement to novel opioid-related substances with increasing frequency, including tramadol analogs and synthetic opioids. This action follows that established pattern.

- O-DSMT is the primary active metabolite of tramadol, a Schedule IV substance. Scheduling the metabolite separately closes a documented gap that the unscheduled research-chemical market has exploited.

- No parallel Congressional scheduling legislation for O-DSMT is currently pending. The DEA acts under its existing emergency scheduling authority, which permits temporary placement for up to two years while permanent rulemaking proceeds.

Materiality Classification

HIGH — The forthcoming temporary order imposes Schedule I criminal and civil sanctions on all handlers of O-DSMT across the regulated population, requiring immediate registration, inventory, and supply-chain review by any firm or institution currently working with the substance or its derivatives.

Intelligence Outlook

Monitor the DEA Federal Register filings for issuance of the temporary scheduling order for O-desmethyltramadol, which will set the operative compliance date.